Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and Software Release
Monday, January 9, 2017
The Sequel System is PacBio’s latest platform based on its Single Molecule, Real-Time (SMRT®) Sequencing technology. Since the launch of the system in fall of 2015, PacBio has installed more than 110 Sequel Systems globally. The latest release includes a new version of the consumable SMRT Cells that is optimized for the new sequencing chemistry kits. The company has also made updates to its base calling algorithm that increase accuracy, and added new features in the Sequel System software package to help support clinical research applications. The V2 chemistry and V4 software updates will be available on
This release improves users’ ability to perform low-fold structural variant detection and key targeted sequencing applications. For structural variant detection, customers can now accomplish the same or better quality of results for structural variant analysis using, on average, half the number of SMRT Cells compared to the previously available chemistry. The increase in read length provided by the new chemistry also enables the detection of larger-scale structural variants; in particular, there is a 3-fold increase in sensitivity of insertions over 5 kb. For targeted sequencing, the new chemistry and software gives users more flexibility. For example, for minor variant detection, customers can either gain detection sensitivity or reduce cost per sample with increased sample multiplexing.
“This release is part of our continued commitment to increasing the performance of the Sequel System, and we are very pleased with the data we are seeing both internally and at our beta-test sites,” said
More information about Sequel is available at: http://www.pacb.com/sequel/.
About Pacific Biosciences
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product improvements, updates or new features, future availability, uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Nicole Litchfield415.793.6468 email@example.com Investors: Trevin Rard650.521.8450 firstname.lastname@example.org
News Provided by Acquire Media